Odekerken Vincent J J, Post Bart, Verschuur Constant V M, de Bie Rob M A
Academisch Medisch Centrum/Universiteit van Amsterdam, afd. Neurologie, Amsterdam, The Netherlands.
Ned Tijdschr Geneeskd. 2009;153:A286.
Parkinson's disease (PD) is a neurodegenerative disorder characterised by tremor, rigidity and bradykinesia. The current treatment, for example with levodopa or dopamine-agonists, is complicated by response fluctuations, dyskinesias and gastro-intestinal side-effects. These, and various other reasons including fear of levodopa toxicity, have led to reluctance in starting medical treatment in PD. Especially during the last decade it has become clear that there is no scientific substrate for this reluctance. The aim should be to minimize the restraints in daily activity caused by PD, where medications including levodopa and dopamine-agonists have proven to be effective.
帕金森病（PD）是一种以震颤、僵硬和运动迟缓为特征的神经退行性疾病。目前的治疗方法，如使用左旋多巴或多巴胺激动剂，会因反应波动、运动障碍和胃肠道副作用而变得复杂。这些以及包括对左旋多巴毒性的恐惧在内的各种其他原因，导致人们在帕金森病开始药物治疗时有所顾虑。特别是在过去十年中，已经很清楚这种顾虑没有科学依据。目标应该是尽量减少帕金森病对日常活动造成的限制，事实证明包括左旋多巴和多巴胺激动剂在内的药物对此有效。
